242 related articles for article (PubMed ID: 36789575)
1. Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer.
Kim JY; Park CK; Noh S; Cheong JH; Noh SH; Kim H
Gut Liver; 2023 Sep; 17(5):753-765. PubMed ID: 36789575
[TBL] [Abstract][Full Text] [Related]
2. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
[TBL] [Abstract][Full Text] [Related]
3. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
Han N; Kim MA; Lee HS; Kim WH
Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer.
Park JH; Kim EK; Kim YH; Kim JH; Bae YS; Lee YC; Cheong JH; Noh SH; Kim H
Gastric Cancer; 2016 Oct; 19(4):1041-1051. PubMed ID: 26573601
[TBL] [Abstract][Full Text] [Related]
6. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
[TBL] [Abstract][Full Text] [Related]
7. Unique characteristics of
Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
[TBL] [Abstract][Full Text] [Related]
8. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
Ye J; Zhou Y; Weiser MR; Gönen M; Zhang L; Samdani T; Bacares R; DeLair D; Ivelja S; Vakiani E; Klimstra DS; Soslow RA; Shia J
Hum Pathol; 2014 Dec; 45(12):2430-6. PubMed ID: 25311944
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer.
Wang X; Che K; Shi T; Liu Q; Xu X; Wu H; Yu L; Liu B; Wei J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1583-1595. PubMed ID: 35294647
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Significance of EBV-Infected Gastric Carcinomas: A Meta-Analysis.
Pyo JS; Kim NY; Kang DW
Medicina (Kaunas); 2020 Jul; 56(7):. PubMed ID: 32668573
[No Abstract] [Full Text] [Related]
15. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.
Huang SC; Ng KF; Yeh TS; Cheng CT; Lin JS; Liu YJ; Chuang HC; Chen TC
Int J Cancer; 2019 Dec; 145(12):3218-3230. PubMed ID: 30771224
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma.
Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A
J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564
[TBL] [Abstract][Full Text] [Related]
17. Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.
Yang L; Wei S; Zhao R; Wu Y; Qiu H; Xiong H
Sci Rep; 2016 Jun; 6():28919. PubMed ID: 27354232
[TBL] [Abstract][Full Text] [Related]
18. CDX-1/CDX-2 Expression Is a Favorable Prognostic Factor in Epstein-Barr Virus-Negative, Mismatch Repair-Proficient Advanced Gastric Cancers.
Kim K; Noh S; Cheong JH; Kim H
Gut Liver; 2021 Sep; 15(5):694-704. PubMed ID: 34312322
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis.
Kang HJ; Lee IS; Park YS; Ho WJ; Sohn D; Ahn JY; Yook JH; Kim BS
Ann Surg Oncol; 2016 Oct; 23(11):3684-3692. PubMed ID: 27221363
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
